Wood Gavin's Form 4 filing
Adaptimmune Therapeutics PLCADAPY · filed May 23, 2022
- Accession no.
- 0001104659-22-064008
- Filed
- May 23, 2022, 9:00 PM ET
- Trade date
- May 20, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $11.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wood GavinCIK 0001577539 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2022 | Ordinary Shares with a nominal value of GBP0.001 per share | PPurchaseAcquired | +39,000 | $0.2904F3 | +$11,325.6 | 96,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 of $0.2904 per ordinary share is derived from the purchase price paid on May 20, 2022 of $1.7423 per ADS divided by six.
Referenced by the price of 1 transaction in Table I.